Inovio Pharmaceuticals (NASDAQ:INO)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Friday, March 22nd, AnalystRatings.com reports. They currently have a $13.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 225.81% from the stock’s current price.
The analysts wrote, “916-3963, Probability of success (POS) Prob-adj Value Full value S/O as of POLT, U.S. 10% $0.03 $0.34 Shares outstanding 33,165 Emricasan for cirrhosis, U.S.””
Other equities analysts have also issued reports about the company. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, March 15th. BidaskClub lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, February 14th. Finally, Maxim Group set a $8.00 price objective on Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, February 20th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $7.57.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). Inovio Pharmaceuticals had a negative net margin of 318.11% and a negative return on equity of 93.39%. The company had revenue of $2.50 million during the quarter, compared to the consensus estimate of $2.69 million. During the same period last year, the company earned ($0.23) earnings per share. Analysts anticipate that Inovio Pharmaceuticals will post -0.99 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in the business. American Century Companies Inc. acquired a new position in Inovio Pharmaceuticals during the 4th quarter worth approximately $495,000. Geode Capital Management LLC boosted its position in Inovio Pharmaceuticals by 14.2% during the 4th quarter. Geode Capital Management LLC now owns 1,004,095 shares of the biopharmaceutical company’s stock worth $4,016,000 after acquiring an additional 124,966 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Inovio Pharmaceuticals by 41.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 737,962 shares of the biopharmaceutical company’s stock worth $2,952,000 after acquiring an additional 217,536 shares during the last quarter. Amalgamated Bank acquired a new position in Inovio Pharmaceuticals during the 4th quarter worth approximately $50,000. Finally, Public Employees Retirement System of Ohio boosted its position in Inovio Pharmaceuticals by 14.9% during the 4th quarter. Public Employees Retirement System of Ohio now owns 224,765 shares of the biopharmaceutical company’s stock worth $899,000 after acquiring an additional 29,136 shares during the last quarter. 36.43% of the stock is owned by hedge funds and other institutional investors.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Recommended Story: How do candlesticks reflect price movement?
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.